Effects of cholestyramine and chenodeoxycholic acid on the metabolism of endogenous triglyceride in hyperlipoproteinemia
- PMID: 731123
Effects of cholestyramine and chenodeoxycholic acid on the metabolism of endogenous triglyceride in hyperlipoproteinemia
Abstract
Previous studies conducted under basal conditions have suggested a linkage between the formation of plasma triglyceride and the degradation of cholesterol to bile acids. To further examine this relationship, plasma endogenous triglyceride kinetics were determined using [(3)H]glycerol in 26 hyperlipidemic subjects before and during stimulated (cholestyramine treatment) and inhibited (chenodeoxycholic acid treatment) bile acid synthesis. All patients with hyperlipoproteinemia (HLP) type II (n = 9) treated with cholestyramine (12 g daily for 2-4 months) displayed increased apparent biosynthesis (12.8 +/- 1.5 vs. 9.7 +/- 1.2 micro mol kg(-1)hr(-1), mean +/- SEM, P < 0.005) and an elevated apparent fractional turnover rate (0.230 +/- 0.017 vs. 0.176 +/- 0.014 hr(-1), P < 0.001) as determined over a 10-hr period, in spite of essentially unchanged plasma triglyceride concentrations. No consistent effect of this therapy was encountered in the five patients studied with type IV HLP. Chenodeoxycholic acid feeding (1.9 mmol daily for 3-4 months) resulted in a reduced apparent synthesis of plasma triglycerides both in type IIa (n = 5, 7.9 +/- 0.5 vs. 13.1 +/- 1.2 micro mol kg(-1)hr(-1), P < 0.01) and type IV HLP (n = 7, 15.5 +/- 1.8 vs. 23.6 +/- 3.7 micro mol kg(-1)hr(-1), P < 0.02). Furthermore, a 20-25% reduction of the apparent fractional turnover rate was seen, and the plasma concentration of triglycerides was reduced by about 15%. It is concluded that the present experimental conditions that primarily influence cholesterol and bile acid biosynthesis also affect the metabolism of plasma triglycerides-and presumably that of very low density lipoprotein-in a regulatory manner. Hypothetically, this may be achieved via a hepatic pool of newly synthesized cholesterol.
Similar articles
-
Bile acid kinetics in relation to endogenous tryglyceride metabolism in various types of hyperlipoproteinemia.J Lipid Res. 1978 Nov;19(8):1004-16. J Lipid Res. 1978. PMID: 731122
-
Effects of cholic acid on the metabolism of endogenous plasma triglyceride and on biliary lipid composition in hyperlipoproteinemia.J Lipid Res. 1980 Jan;21(1):1-9. J Lipid Res. 1980. PMID: 7354246
-
Plasma cholesterol esterification rate in type IV hyperlipoproteinemia. Relation to bile acid kinetics and triglyceride metabolism.J Lab Clin Med. 1981 Apr;97(4):502-10. J Lab Clin Med. 1981. PMID: 7205058
-
Ursodeoxycholic acid treatment in humans: effects on plasma and biliary lipid metabolism with special reference to very low density lipoprotein triglyceride and bile acid kinetics.Eur J Clin Invest. 1986 Apr;16(2):169-77. doi: 10.1111/j.1365-2362.1986.tb01325.x. Eur J Clin Invest. 1986. PMID: 3089812
-
Changes in plasma triglyceride metabolism during withdrawal of bile.Metabolism. 1976 Nov;25(11):1259-68. doi: 10.1016/s0026-0495(76)80009-1. Metabolism. 1976. PMID: 185488
Cited by
-
Bile Acid Signaling in Metabolic and Inflammatory Diseases and Drug Development.Pharmacol Rev. 2024 Oct 16;76(6):1221-1253. doi: 10.1124/pharmrev.124.000978. Pharmacol Rev. 2024. PMID: 38977324 Review.
-
Bile salt hydrolase catalyses formation of amine-conjugated bile acids.Nature. 2024 Feb;626(8000):859-863. doi: 10.1038/s41586-023-06990-w. Epub 2024 Feb 7. Nature. 2024. PMID: 38326609 Free PMC article.
-
In Silico Development of Combinatorial Therapeutic Approaches Targeting Key Signaling Pathways in Metabolic Syndrome.Pharm Res. 2022 Nov;39(11):2937-2950. doi: 10.1007/s11095-022-03231-z. Epub 2022 Mar 21. Pharm Res. 2022. PMID: 35313359
-
Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology.Nat Rev Gastroenterol Hepatol. 2022 Jul;19(7):432-450. doi: 10.1038/s41575-021-00566-7. Epub 2022 Feb 14. Nat Rev Gastroenterol Hepatol. 2022. PMID: 35165436 Review.
-
Bile Acid and Cholesterol Metabolism in Atherosclerotic Cardiovascular Disease and Therapy.Cardiol Plus. 2020;5(4):159-170. Epub 2020 Dec 30. Cardiol Plus. 2020. PMID: 34350368 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
